INFORMATION FOR PROVIDERS

Providers are asked to maintain a high degree of suspicion for MIS-C in pediatric patients presenting with Kawasaki Disease-like features, ill children with persistent fever without a clear clinical source, and ill individuals with fever who have been previously exposed to COVID-19.

Reporting
Health care providers are asked to report cases of MIS-C to local or state public health as soon as possible following diagnoses.

• MDHHS and local health department contacts and reporting guidance
• MDHHS Division of Communicable Disease can be reached for assistance at 517-335-8165.
• MIS-C Mortality Investigation and Reporting Guidance for Medical Examiners, Pathologists and Healthcare Providers

Research

• Study of MIS-C Patients at Detroit-area Hospital System
• Trends in Geographic and Temporal Distribution of US Children With Multisystem Inflammatory Syndrome During the COVID-19 Pandemic
• Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19
• Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children
• A National Consensus Management Pathway for Paediatric Inflammatory Multisystem Syndrome Temporally Associated with COVID-19 (PIMS-TS): Results of a National Delphi Process

Resources

• CDCs Information for Healthcare Providers about Multisystem Inflammatory Syndrome in Children (MIS-C)
• MIS-C Job Aid for Clinicians
• MIS-C Fast Fact Sheet
• CDC Case Definition
• Evaluation and Treatment Information
• AAP MIS-C Interim Guidance
• An Open Letter to Michigan Healthcare Professionals and Families from Michigan's Children's Hospitals Clinical Leadership Collaborative and the MHA
• OPENPediatrics: "Characteristics and Outcomes of U.S. Children and Adolescents with MIS-C" by Dr. Adrienne Randolph